TapewireFind a company

organization · Reporting owner

Braslyn Ltd.

Disclosed activity across 6 companies

Tapewire entity
94911
SEC CIK
0001642355

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Esperion Therapeutics, Inc.ESPR · Entity 3079610% ownerOctober 26, 2018October 30, 2018
INSEEGO CORP.INSG · Entity 706110% ownerDecember 14, 2020December 16, 2020
Mirati Therapeutics, Inc.MRTX · Entity 94908See remarksJanuary 23, 2024January 25, 2024
Solid Biosciences Inc.SLDB · Entity 491510% ownerMarch 04, 2019March 06, 2019
Tango Therapeutics, Inc.TNGX · Entity 149710% ownerAugust 10, 2021January 04, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Esperion Therapeutics, Inc.

Report date October 26, 2018 · Filed October 30, 2018

Jointly reported with Boxer Asset Management Inc., Tuesday Thirteen Inc., LEWIS JOSEPH, Boxer Capital, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,401,000 Reported balance Holding disclosure · report date 2018-10-26 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 1,401,000

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Tuesday Thirteen Inc. ("Tuesday Thirteen") and (v) Joseph C. Lewis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect1,201,250 Reported balance Holding disclosure · report date 2018-10-26 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,201,250

F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

Common StockSEC Table I · non-derivativeDirect100 Reported balance Holding disclosure · report date 2018-10-26 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 100

F3: These securities are owned directly by Tuesday Thirteen and indirectly by Joseph C. Lewis.

Call OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.00 · Expires 2019-03-15DirectNot disclosed Reported balance Holding disclosure · report date 2018-10-26 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

Call OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2019-03-15DirectNot disclosed Reported balance Holding disclosure · report date 2018-10-26 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance Not disclosed

F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Tuesday Thirteen Inc. ("Tuesday Thirteen") and (v) Joseph C. Lewis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

F2: These securities are owned directly by Boxer Capital and indirectly by Boxer Management and Joseph C. Lewis.

F3: These securities are owned directly by Tuesday Thirteen and indirectly by Joseph C. Lewis.

INSEEGO CORP.

Report date December 14, 2020 · Filed December 16, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,614,830 Last balance in matching sequence After 2020-12-16 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rows

Row 1 · 2020-12-14 · Sale · Disposed 1,721,783 · Balance 8,278,217

F2: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $15.01 to $16.005.

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Row 2 · 2020-12-14 · Sale · Disposed 178,949 · Balance 8,099,268

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $16.01 to $16.38.

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Row 3 · 2020-12-15 · Sale · Disposed 190,590 · Balance 7,908,678

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.50 to $15.20.

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Row 4 · 2020-12-16 · Sale · Disposed 293,848 · Balance 7,614,830

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.00 to $14.70.

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

F2: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $15.01 to $16.005.

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $16.01 to $16.38.

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.50 to $15.20.

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.00 to $14.70.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Filing footnotes · ownership attribution and instrument terms

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

Solid Biosciences Inc.

Report date March 04, 2019 · Filed March 06, 2019

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,923,272 Reported balance Holding disclosure · report date 2019-03-04 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 3,923,272

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect11,488 Reported balance Holding disclosure · report date 2019-03-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 11,488

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect30,210 Reported balance Holding disclosure · report date 2019-03-04 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 30,210

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Tango Therapeutics, Inc.

Report date August 10, 2021 · Filed January 04, 2022

Jointly reported with LEWIS JOSEPH

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect26,961 Reported balance Holding disclosure · report date 2021-08-10 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 26,961

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Joseph C. Lewis, (v) BCTG Holdings, LLC, (vi) MVA Investors, LLC and (vii) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis who is the sole indirect beneficial owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) Joseph C. Lewis, (v) BCTG Holdings, LLC, (vi) MVA Investors, LLC and (vii) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Joseph C. Lewis who is the sole indirect beneficial owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Pandion Therapeutics, Inc.

Report date July 21, 2020 · Filed July 21, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I., MVA Investors, LLC

Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,107,513 Last balance in matching sequence After 2020-07-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote23,622 Reported balance After 2020-07-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-07-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote0 Reported balance After 2020-07-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerWarrant (right to purchase) · Derivative 1,413,475 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · derivative · entry 8

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,413,475 shares

Expires not disclosed

F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerWarrant (right to purchase) · Derivative 3,578,036 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · derivative · entry 7

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,578,036 shares

Expires not disclosed

F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerWarrant (right to purchase) · Derivative 332,809 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · derivative · entry 6

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 332,809 shares

Expires not disclosed

F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerCommon Stock 30,518 Not disclosed Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 5

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F6 · ownership.nature: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerCommon Stock 3,135,966 Not disclosed Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 4

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerCommon Stock 203,754 Not disclosed Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 3

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F4 · ownership.nature: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerCommon Stock 3,201,440 Not disclosed Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 2

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:32 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Disposition to issuerCommon Stock 287,866 Not disclosed Not disclosed
Disclosure

SEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 1

Boxer Capital, LLC · CIK 0001465837 · See remarks

Boxer Asset Management Inc. · CIK 0001465836 · See remarks

LEWIS JOSEPH · CIK 0001015747 · See remarks

MVA Investors, LLC · CIK 0001468223 · See remarks

Davis Aaron I. · CIK 0001465914 · See remarks

Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks

Fuglesang Christopher · CIK 0001465835 · See remarks

Braslyn Ltd. · CIK 0001642355 · See remarks

Lockend Five, LLC · CIK 0001830602 · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1 $195.90 $195.90
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 11

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,966

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionCommon Stock 410 $0.00 $0.41
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 10

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 200 $198.00 $39,600.00
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 9

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,557

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 20 $196.12 $3,922.40
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 8

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,757

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 189 $195.52 $36,953.28
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 7

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,777

F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $195.11 to $196.09.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1 $191.00 $191.00
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 6

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,966

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionCommon Stock 11,971 $0.00 $11.97
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 5

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 2,237 $199.08 $445,341.96
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 4

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,123,996

F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $198.62 to $199.46.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 3,993 $197.81 $789,855.33
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 3

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,126,233

F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $197.56 to $198.23.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 4,633 $197.30 $914,090.90
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 2

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,130,226

F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $196.55 to $197.53.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 21:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1,107 $195.82 $216,772.74
Disclosure

SEC source: 0000899243-21-011086 · doc4.xml · nonDerivative · entry 1

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,134,859

F2 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $195.24 to $196.20.

F1 · ownership.direct: Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
December 16, 2020 Filed Dec 16, 2020 22:42 UTC INSEEGO CORP. INSG · Entity 7061 SaleCommon Stock 293,848 $14.37 $4,224,035.62
Disclosure

SEC source: 0000899243-20-034137 · doc4.xml · nonDerivative · entry 4

Braslyn Ltd. · CIK 0001642355 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,614,830

F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.00 to $14.70.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Read SEC document
December 15, 2020 Filed Dec 16, 2020 22:42 UTC INSEEGO CORP. INSG · Entity 7061 SaleCommon Stock 190,590 $14.81 $2,822,199.54
Disclosure

SEC source: 0000899243-20-034137 · doc4.xml · nonDerivative · entry 3

Braslyn Ltd. · CIK 0001642355 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,908,678

F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $14.50 to $15.20.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Read SEC document
December 14, 2020 Filed Dec 16, 2020 22:42 UTC INSEEGO CORP. INSG · Entity 7061 SaleCommon Stock 178,949 $16.07 $2,875,710.43
Disclosure

SEC source: 0000899243-20-034137 · doc4.xml · nonDerivative · entry 2

Braslyn Ltd. · CIK 0001642355 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,099,268

F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $16.01 to $16.38.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Read SEC document
December 14, 2020 Filed Dec 16, 2020 22:42 UTC INSEEGO CORP. INSG · Entity 7061 SaleCommon Stock 1,721,783 $15.62 $26,891,667.79
Disclosure

SEC source: 0000899243-20-034137 · doc4.xml · nonDerivative · entry 1

Braslyn Ltd. · CIK 0001642355 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,278,217

F2 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $15.01 to $16.005.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd. ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of Braslyn, Golden Harbor Ltd., Tavistock Financial, LLC and Joseph C. Lewis. Mr. Lewis is the sole indirect beneficial owner of and controls Braslyn.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionWarrant (right to purchase) · Derivative 104,565 $5.60 Strike: $0.00 $585,459.44
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · derivative · entry 31

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,590,421

Underlying: Common Stock · 104,565 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Tax withholdingCommon Stock 1 $202.25 $202.25
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 29

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,966

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionCommon Stock 104,565 $0.00 $104.57
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 28

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 818 $220.02 $179,979.63
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 27

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,031,402

F27 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $220.00 to $220.17.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 663 $218.85 $145,097.55
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 26

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,032,220

F26 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $218.62 to $219.08.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 5,912 $218.04 $1,289,025.28
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 25

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,032,883

F25 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $217.63 to $218.59.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 6,775 $217.14 $1,471,156.70
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 24

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,038,795

F24 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $216.63 to $217.62.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 11,656 $216.06 $2,518,338.25
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 23

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,045,570

F23 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $215.62 to $216.61.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 27,992 $215.08 $6,020,396.20
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 22

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,057,226

F22 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $214.61 to $215.605.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 2,344 $214.31 $502,335.37
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 21

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,085,218

F21 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $213.61 to $214.57.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 3,108 $212.66 $660,946.66
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 20

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,087,562

F20 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $212.13 to $212.98.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 14,408 $211.50 $3,047,339.55
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 19

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,090,670

F19 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $211.07 to $212.045.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 10,599 $210.58 $2,231,944.84
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 18

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,105,078

F18 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $210.06 to $211.03.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 15,091 $209.66 $3,163,970.01
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 17

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,115,677

F17 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $209.05 to $210.04.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1,674 $208.78 $349,497.89
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 16

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,130,768

F16 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $208.50 to $209.04.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1,086 $207.96 $225,849.23
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 15

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,132,442

F15 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $207.475 to $208.32.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 1,088 $206.50 $224,670.91
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 14

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,133,528

F14 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $206.12 to $207.03.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 800 $205.64 $164,515.84
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 13

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,134,616

F13 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $205.12 to $206.00.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 29, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 550 $203.32 $111,827.54
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 12

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,416

F12 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $203.03 to $203.69.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionWarrant (right to purchase) · Derivative 295,438 $5.60 Strike: $0.00 $1,654,157.36
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · derivative · entry 30

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,694,986

Underlying: Common Stock · 295,438 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Tax withholdingCommon Stock 2 $209.16 $418.32
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 11

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,966

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 Exercise / conversionCommon Stock 295,438 $0.00 $295.44
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 10

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,135,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 500 $211.06 $105,531.50
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 9

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,840,530

F10 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $211.06 to $211.065.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 23,283 $210.31 $4,896,647.73
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 8

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,841,030

F9 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $210.00 to $210.99.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 37,428 $209.47 $7,840,043.16
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 7

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,864,313

F8 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $209.00 to $209.99.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 25,036 $208.40 $5,217,502.40
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 6

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,901,741

F7 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $208.00 to $208.995.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 28, 2020 Filed Oct 30, 2020 21:53 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 SaleCommon Stock 38,525 $207.35 $7,988,158.75
Disclosure

SEC source: 0000899243-20-030059 · doc4.xml · nonDerivative · entry 5

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,926,777

F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $207.00 to $207.99.

F1 · ownership.direct: These securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.